Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice.

COVID-19 GS-441524 RNA-dependent RNA polymerase RdRp SARS-CoV-2 antiviral coronavirus mouse remdesivir therapeutic

Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
21 07 2020
Historique:
received: 21 04 2020
revised: 02 06 2020
accepted: 30 06 2020
pubmed: 16 7 2020
medline: 16 7 2020
entrez: 16 7 2020
Statut: ppublish

Résumé

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the novel viral disease COVID-19. With no approved therapies, this pandemic illustrates the urgent need for broad-spectrum antiviral countermeasures against SARS-CoV-2 and future emerging CoVs. We report that remdesivir (RDV) potently inhibits SARS-CoV-2 replication in human lung cells and primary human airway epithelial cultures (EC

Identifiants

pubmed: 32668216
pii: S2211-1247(20)30921-9
doi: 10.1016/j.celrep.2020.107940
pmc: PMC7340027
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107940

Subventions

Organisme : NIAID NIH HHS
ID : T32 AI007151
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI108197
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI142759
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI132178
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK065988
Pays : United States

Commentaires et corrections

Type : UpdateOf

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Interests The authors affiliated with Gilead Sciences, Inc. are employees of the company and may own company stock.

Références

Antiviral Res. 2020 Jun;178:104793
pubmed: 32283108
J Virol. 2019 Nov 26;93(24):
pubmed: 31578288
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Antiviral Res. 2019 Sep;169:104541
pubmed: 31233808
Expert Opin Drug Metab Toxicol. 2012 Jun;8(6):665-76
pubmed: 22509856
Cell. 2020 Jul 23;182(2):429-446.e14
pubmed: 32526206
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
N Engl J Med. 2020 Mar 5;382(10):929-936
pubmed: 32004427
PLoS One. 2015 Jun 26;10(6):e0131451
pubmed: 26115403
Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):3048-53
pubmed: 26976607
Nat Rev Microbiol. 2016 Aug;14(8):523-34
pubmed: 27344959
N Engl J Med. 2020 Jun 11;382(24):2327-2336
pubmed: 32275812
J Biol Chem. 2020 May 15;295(20):6785-6797
pubmed: 32284326
J Virol. 2005 Dec;79(24):15511-24
pubmed: 16306622
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Respirology. 2003 Nov;8 Suppl:S9-14
pubmed: 15018127
Antiviral Res. 2020 Jun;178:104786
pubmed: 32251767
Antimicrob Agents Chemother. 2020 Jun 23;64(7):
pubmed: 32366720
PLoS One. 2010 Jan 15;5(1):e8729
pubmed: 20090954
Pharmacol Res. 2020 Jun;156:104761
pubmed: 32205232
Sci Transl Med. 2017 Jun 28;9(396):
pubmed: 28659436
J Med Chem. 2018 Mar 22;61(6):2211-2226
pubmed: 28792763
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Lancet Infect Dis. 2020 Apr;20(4):411-412
pubmed: 32105638
Sci Rep. 2017 Mar 06;7:43395
pubmed: 28262699
Emerg Infect Dis. 2020 Sep;26(9):
pubmed: 32412897
Nat Commun. 2019 May 28;10(1):2342
pubmed: 31138817
Sci Transl Med. 2020 Apr 29;12(541):
pubmed: 32253226
J Virol. 2020 Mar 17;94(7):
pubmed: 31996437
mBio. 2018 Mar 6;9(2):
pubmed: 29511076
Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6771-6776
pubmed: 32054787
N Engl J Med. 2017 Feb 9;376(6):584-594
pubmed: 28177862
Euro Surveill. 2017 Mar 30;22(13):
pubmed: 28382917
Proc Natl Acad Sci U S A. 2010 Dec 28;107(52):22505-10
pubmed: 21148772
N Engl J Med. 2019 Dec 12;381(24):2293-2303
pubmed: 31774950
Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12995-3000
pubmed: 14569023
J Biol Chem. 2020 Apr 10;295(15):4773-4779
pubmed: 32094225
Emerg Infect Dis. 2020 Jun;26(6):1266-1273
pubmed: 32160149
Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16157-62
pubmed: 24043791
Nature. 2016 Mar 17;531(7594):381-5
pubmed: 26934220
Science. 2020 May 15;368(6492):779-782
pubmed: 32277040
Curr Med Chem. 2013;20(34):4241-8
pubmed: 23992317
Nat Commun. 2020 Jan 10;11(1):222
pubmed: 31924756
Science. 2020 Jun 26;368(6498):1499-1504
pubmed: 32358203
Bioorg Med Chem Lett. 2012 Apr 15;22(8):2705-7
pubmed: 22446091
J Virol. 2013 Dec;87(23):12611-8
pubmed: 24027335
Nat Med. 2015 Dec;21(12):1508-13
pubmed: 26552008
JAMA. 2020 May 12;323(18):1824-1836
pubmed: 32282022
Glob Chall. 2017 Jan 10;1(1):33-46
pubmed: 31565258
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Methods Mol Med. 2005;107:183-206
pubmed: 15492373
Nat Med. 2004 Dec;10(12 Suppl):S88-97
pubmed: 15577937
Microbes Infect. 2020 Mar;22(2):69-71
pubmed: 32032682
Science. 2015 Feb 13;347(6223):771-5
pubmed: 25678663
Antiviral Res. 2017 Oct;146:161-163
pubmed: 28912011
Emerg Infect Dis. 2004 Sep;10(9):1550-7
pubmed: 15498155
Nature. 2020 Sep;585(7824):273-276
pubmed: 32516797

Auteurs

Andrea J Pruijssers (AJ)

Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Institute for Infection, Immunology, and Inflammation, Nashville, TN 37232, USA. Electronic address: ardina.pruijssers@vumc.org.

Amelia S George (AS)

Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Institute for Infection, Immunology, and Inflammation, Nashville, TN 37232, USA.

Alexandra Schäfer (A)

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Sarah R Leist (SR)

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Lisa E Gralinksi (LE)

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Kenneth H Dinnon (KH)

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Boyd L Yount (BL)

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Maria L Agostini (ML)

Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Institute for Infection, Immunology, and Inflammation, Nashville, TN 37232, USA.

Laura J Stevens (LJ)

Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Institute for Infection, Immunology, and Inflammation, Nashville, TN 37232, USA.

James D Chappell (JD)

Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Institute for Infection, Immunology, and Inflammation, Nashville, TN 37232, USA.

Xiaotao Lu (X)

Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Institute for Infection, Immunology, and Inflammation, Nashville, TN 37232, USA.

Tia M Hughes (TM)

Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Institute for Infection, Immunology, and Inflammation, Nashville, TN 37232, USA.

Kendra Gully (K)

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

David R Martinez (DR)

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Ariane J Brown (AJ)

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Rachel L Graham (RL)

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Jason K Perry (JK)

Gilead Sciences, Inc., Foster City, CA 94404, USA.

Venice Du Pont (V)

Gilead Sciences, Inc., Foster City, CA 94404, USA.

Jared Pitts (J)

Gilead Sciences, Inc., Foster City, CA 94404, USA.

Bin Ma (B)

Gilead Sciences, Inc., Foster City, CA 94404, USA.

Darius Babusis (D)

Gilead Sciences, Inc., Foster City, CA 94404, USA.

Eisuke Murakami (E)

Gilead Sciences, Inc., Foster City, CA 94404, USA.

Joy Y Feng (JY)

Gilead Sciences, Inc., Foster City, CA 94404, USA.

John P Bilello (JP)

Gilead Sciences, Inc., Foster City, CA 94404, USA.

Danielle P Porter (DP)

Gilead Sciences, Inc., Foster City, CA 94404, USA.

Tomas Cihlar (T)

Gilead Sciences, Inc., Foster City, CA 94404, USA.

Ralph S Baric (RS)

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Mark R Denison (MR)

Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Institute for Infection, Immunology, and Inflammation, Nashville, TN 37232, USA; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.

Timothy P Sheahan (TP)

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Electronic address: sheahan@email.unc.edu.

Classifications MeSH